Developments in the therapeutic landscape for dry eye
The evolving understanding of DED supports a shift toward mechanism-based, personalized management that addresses inflammation, tear film instability, neurosensory dysfunction, and glandular insufficiency. Integrating targeted therapies, device-based interventions, and regenerative approaches with improved diagnostics may enable more predictable, proactive care. Rigorous research is still needed to optimize treatment selection and sequencing.
Authors
- Giuseppe Giannaccare (ORCID: https://orcid.org/0000-0003-2617-0289)
- Vincenzo Scorcia (ORCID: https://orcid.org/0000-0001-6826-7957)
- Giulia Coco (ORCID: https://orcid.org/0009-0007-5459-566X)
- Andrea Lucisano (ORCID: https://orcid.org/0000-0003-1382-0828)
- Linda Marie Louise Busin
- Massimiliano Borselli
- Costanza Rossi
Institutions
- University of Rome Tor Vergata (IT)
- University of Cagliari (IT)
- Magna Graecia University (IT)
- Fatebenefratelli Hospital (IT)
Publication Details
- Journal
- Expert Opinion on Pharmacotherapy
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1080/14656566.2026.2633382
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 0.00